<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904277</url>
  </required_header>
  <id_info>
    <org_study_id>04302018.049</org_study_id>
    <nct_id>NCT03904277</nct_id>
  </id_info>
  <brief_title>Does Patent Foramen Ovale Size Matter in Men and Women</brief_title>
  <official_title>Does Patent Foramen Ovale Size Matter in Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oregon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oregon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A patent foramen ovale (PFO) is present in ~30% of the general population. The PFO has
      historically been considered to be trivial. However, recent work by the investigator's group
      and others has identified that, compared to individuals without a PFO, those with a PFO have
      worse pulmonary gas exchange efficiency, have a higher core body temperature, blunted
      ventilatory responses to chronic hypoxia and acute carbon dioxide and increased
      susceptibility to altitude illnesses such as acute mountain sickness, and high altitude
      pulmonary edema (Lovering, Elliott &amp; Davis J Appl Physiol 2016). Specific to this
      application,subjects with a PFO may have worse pulmonary gas exchange efficiency because a
      PFO is a potential source of right-to-left shunt that will make pulmonary gas exchange
      efficiency worse. If true, then this may negatively impact exercise capacity and/or exercise
      tolerance. Further, in those with a PFO compared to those without, preliminary work from the
      investigator's lab indicates that there may be an effect of PFO size on pulmonary gas
      exchange efficiency. This is such that those with a large PFO (grade 3 or higher) display
      significantly worse gas exchange efficiency compared to those with a small (grade 2 or lower)
      or no PFO,even at low exercise workloads. Additionally, the investigators were curious as to
      whether there would be a sex effect, but due to logistical constraints, the investigators
      were unable to recruit an equal number of female and male subjects. Thus, in addition to the
      potential size effect on the investigators outcome measures, the investigators would like to
      build on this work by examining the potential effect of biological sex. Although a PFO has
      been traditionally considered to have a minimal impact of physiology and pathophysiology,
      emerging evidence suggests this may not be the case. The investigator's lab is focused on
      understanding how and why a relatively small hole in the heart (PFO) can have a relatively
      large impact on cardiopulmonary and respiratory physiology, and how these impacts may be
      based on the size of the PFO.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>alveolar-arterial difference in oxygen</measure>
    <time_frame>Baseline</time_frame>
    <description>difference in the partial pressure of oxygen between the alveoli (calculated) and arterial blood (direct measure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>aerobic exercise capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>ability to utilize oxygen while exercising, AKA Vo2MAX</description>
  </primary_outcome>
  <primary_outcome>
    <measure>six-minute walk test</measure>
    <time_frame>Baseline</time_frame>
    <description>distance covered in 6 minutes of walking</description>
  </primary_outcome>
  <primary_outcome>
    <measure>minute flow of intrapulmonary areterio-venous anastamoses (QIPAVA)</measure>
    <time_frame>Baseline</time_frame>
    <description>minute flow through intrapulmonary arteriovenous anastamoses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>core body temperature</measure>
    <time_frame>Baseline</time_frame>
    <description>subject's core body temperature as measured through an ingestible pill</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of tumor necrosis factor alpha</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of C-C motif cytokine 2</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interferon alpha 2</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interferon gamma</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 1 beta</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 6</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 8</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 10</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 12p70</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 17 alpha</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 18</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 23</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of interleukin 33</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of myoglobin</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of myeloid-related protein 8/14</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of neutrophil gelatinase-associated lipocalin</measure>
    <time_frame>Baseline and 3 months post percutaneous closure</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of c-reactive protein</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>matrix metallopeptidase 2</measure>
    <time_frame>Baseline and 3 months post percutaneous closure</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of osteopontin</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of myloperoxidase</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of Serum amyloid A</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of insulin like growth factor binding protein 4</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of intracellular adhesion molecule 1</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of vascular cell adhesion protein 1</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of metallopeptidase 9</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>level of Cystatin C</measure>
    <time_frame>Baseline</time_frame>
    <description>inflammatory marker</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>No PFO</arm_group_label>
    <description>Research subjects who present no evidence of PFO - IE no appearance of saline contrast microbubbles within 3 cardiac cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small PFO</arm_group_label>
    <description>Research subjects who present evidence of having a small PFO or ASD - IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Large PFO</arm_group_label>
    <description>Research subjects who present evidence of having a large PFO - IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma from venous blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adults aged 18-40 with and without a PFO.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18-40

          -  Known to have/not have a PFO.

        Exclusion Criteria:

          -  Previous history of coronary artery disease(ischemic heart disease such as angina,
             heart attack, myocardial infarction).

          -  Failure of Modified Allen's Test in both hands.

          -  Currently taking medications or herbal supplements for any heart or respiratory
             disease that they cannot stop taking for 48 hrsprior to testing (seasonal allergy
             medication not included in exclusion medications).

          -  Lidocaine, nitroglycerine or heparin allergy.

          -  Women who are pregnant or trying to become pregnant.

          -  Previous history of any condition that would prevent the subject from performing cycle
             ergometer exercise (for exercise study only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Lovering, PhD</last_name>
    <phone>541-346-0831</phone>
    <email>lovering@uorgeon.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiorespiratory and Pulmonary Physiology Lab</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Lovering, PhD</last_name>
      <phone>541-346-0831</phone>
      <email>lovering@uoregon.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03904277/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

